



# Empaveli in the UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

HEMATOLOGY / COMPLEMENT · PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

## The clinical situation

Empaveli (pegcetacoplan) is a first-in-class C3 complement inhibitor, FDA-approved for paroxysmal nocturnal hemoglobinuria (PNH) in adults. Manufactured by Apellis Pharmaceuticals, it addresses residual extravascular haemolysis that can persist on C5-only inhibition. Delivered as a 1,080 mg subcutaneous infusion twice weekly via a pump device, approximately 30 minutes per session. It carries a US boxed warning regarding serious infections caused by encapsulated bacteria, which is why pneumococcal, meningococcal (A/C/W/Y and B), and Hib vaccination per current ACIP recommendations is a gating step before therapy begins.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms PNH diagnosis (flow cytometry), documents any prior C5-inhibitor exposure and residual extravascular haemolysis evidence.
- 2 Vaccination program.** Pneumococcal, meningococcal (A/C/W/Y and B), and Hib vaccinations per ACIP, ideally completed at least 2 weeks before first dose.
- 3 MoHAP / DoH / DHA named-patient application.** Physician or hospital pharmacy files dossier: rationale, patient reference, vaccination documentation, twice-weekly dosing plan and pump-training plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- 5 Arrival & pump training.** Cold-chain (2–8°C) delivery; treating centre trains patient or caregiver on the SC infusion pump; maintenance delivered at home twice weekly under physician supervision.

### Indicative economics

**Reference US cash-pay range:** USD 450,000–600,000 annualised at US list for PNH (Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete MoHAP application to first dispensation; vaccination lead time may extend this. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and MoHAP review, including the encapsulated-organism vaccination block. **Logistics.** Cold-chain (2–8°C) shipment with continuous temperature monitoring and importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Empaveli × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/empaveli-uae.html](https://reservemed.com/access-guides/empaveli-uae.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team